|
Gene: IGLV2-14 |
Gene summary for IGLV2-14 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IGLV2-14 | Gene ID | 28815 |
Gene name | immunoglobulin lambda variable 2-14 | |
Gene Alias | IGLV214 | |
Cytomap | 22q11.22 | |
Gene Type | other | GO ID | GO:0002250 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28815 | IGLV2-14 | PTCwithHT_1 | Human | Thyroid | HT | 4.24e-05 | 7.20e-01 | 0.0238 |
28815 | IGLV2-14 | PTCwithHT_6 | Human | Thyroid | HT | 7.43e-16 | 7.24e-01 | 0.02 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGLV2-14 | SNV | Missense_Mutation | rs565111514 | c.345C>A | p.Ser115Arg | p.S115R | P01704 | IG_V_gene | tolerated_low_confidence(0.06) | benign(0.286) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLV2-14 | SNV | Missense_Mutation | rs372979635 | c.209A>C | p.Tyr70Ser | p.Y70S | P01704 | IG_V_gene | deleterious_low_confidence(0.01) | benign(0.177) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.73N>G | p.Gln25Glu | p.Q25E | P01704 | IG_V_gene | deleterious_low_confidence(0) | possibly_damaging(0.774) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.207N>G | p.Ile69Met | p.I69M | P01704 | IG_V_gene | deleterious_low_confidence(0.01) | possibly_damaging(0.685) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.249C>A | p.Phe83Leu | p.F83L | P01704 | IG_V_gene | deleterious_low_confidence(0.02) | benign(0.433) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.349N>T | p.Thr117Ser | p.T117S | P01704 | IG_V_gene | tolerated_low_confidence(0.42) | benign(0.01) | TCGA-AG-4001-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.11N>A | p.Ala4Asp | p.A4D | P01704 | IG_V_gene | deleterious_low_confidence(0.02) | benign(0.02) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.214N>A | p.Val72Ile | p.V72I | P01704 | IG_V_gene | tolerated_low_confidence(0.3) | benign(0.103) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
IGLV2-14 | SNV | Missense_Mutation | novel | c.272C>A | p.Thr91Lys | p.T91K | P01704 | IG_V_gene | deleterious_low_confidence(0) | possibly_damaging(0.767) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
IGLV2-14 | SNV | Missense_Mutation | rs373891287 | c.156C>A | p.Asn52Lys | p.N52K | P01704 | IG_V_gene | deleterious_low_confidence(0.03) | benign(0.076) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |